Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Disease
Conditions
Keywords
Biochemical markers
Brief summary
Ulcerative colitis (UC) and Crohn's disease (CD) are chronic relapsing inflammatory bowel diseases (IBD). At the time of diagnosis it is not possible to predict the course of the disease, which can range from a few flares in a lifetime to uncontrollable disease leading to hospitalization, surgery and stoma. There is a continuous need to improve diagnostic and prognostic tools. In chronic inflammation diseases there is an excessive turnover of the extracellular tissue. Tissue is broken down to small fragments and released into the circulation. Changes in the amount of these fragments in the blood may provide information on the damage and quality of the affected tissue and may therefore act as objective measure of disease burden and severity - a so called biomarker. The potential of such biomarkers is evaluated in a combined cross-sectional and longitudinal survey including 300 patients with UC, CD, irritable bowel disease and healthy controls. The patients are followed for up to 1 year. Changes in biomarker are correlated to standard markers of inflammation during active disease and remission. Perspective The use of new biomarkers may offer a tool to evaluate early changes in the gut of patients with IBD, may be a supplement to the diagnosis, serve as markers for effect of treatment and prognosis, and in time be a good alternative to fecal samples or endoscopy.
Interventions
None listed
Sponsors
University of Southern Denmark
Line Elberg Godskesen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age ≥18 years * Written informed consent * and one of: * for Crohn's disease - active disease: Verified CD diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index \> 4. * for Crohn's disease - disease in remission: Verified CD diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index ≤ 4. * Ulcerative colitis - active disease: Verified UC diagnosis according to clinical, endoscopic and histological standard criteria and SCCAI \> 3. * Ulcerative colitis - in remission: Verified UC diagnosis according to clinical, endoscopic and histological standard criteria and SCCAI ≤ 3. * Irritable bowel syndrome: Verified IBS according to standard criteria. * Healthy control: No known chronic diseases which needs continuously medication.
Exclusion criteria
* Common to all participants: * Patient with ostomy or pouch. * The patient has had colon cancer, dysplasia or adenomatous polyps in the colon during the recent 5 year * The patient is in a poor general condition. * The patient is pregnant at the time of inclusion or has planned pregnancy during the period of study. * The patient cannot understand the information material. * Healthy control: * The patient has a chronic disease. * IBS symptoms according to standard criteria. * The patient has had any type of illness within the last 14 days (for example diarrhea, a cold etc.). * The patient has any type of on-going medication or new medication within the last 14 days (except contraceptive pills and vitamins).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum markers of extracellular matrix proteins (C1M, C3M, C4M, C5M, P1NP, VICM, P1NP, EL-NE, BGM and Pro-C5) | Follow-up of 1 year for patients with active IBD. For all other groups the study are cross-sectional | The biomarkers are evaluated in relation to type of disease and disease activity. |
Countries
Denmark
Outcome results
None listed